Soluble B7-H3 as a Biomarker for Osteosarcoma

Key facts

Sponsor

Peking University People's Hospital

Intervention

ELISA: enzyme-linked immunosorbent assay(diagnostic_test)

Enrollment

200 target

Eligibility

12 years · All sexes

Timeline

2023 – 2024

Study locations (1)

• Peking University People's Hospital, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Osteosarcoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07477457
  A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE1NCT06492954
  Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
  Emory University
• RECRUITINGNANCT07129226
  Musculoskeletal Cancers Remote Monitoring and Care
  Case Comprehensive Cancer Center
• RECRUITINGPHASE1NCT07144254
  Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
  Emory University
• RECRUITINGPHASE1NCT07227571
  Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE1NCT07052383
  Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
  Tcelltech Inc.
• RECRUITINGPHASE1, PHASE2NCT06892678
  DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
  Montefiore Medical Center
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05660408
  RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors
  University of Florida

See all trials for Osteosarcoma →